Kymera Therapeutics Inc. Stock News

Kymera Therapeutics has nine programs in its pipeline. It has a collaboration with Sanofi on its lead therapy IRAK-4.

WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m

Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug Designation for KT-253, a potential treatment for

Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Justin

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m

While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept so

Kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety issues, hurt its stock. When partner Sanofi produces phase 2 data, this company will be considera

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder, President and CEO

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.71 per share a year ago.

WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small

Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.

WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder & Chief Exec

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the

Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences